Primary Peritoneal Cancer trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Primary Peritoneal Cancer. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month4 studies across 4 companies, in the next 180 days.
August 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| CORT | Corcept Therapeutics | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological CancersNCT06906341Progression-Free Survival (PFS) | Phase 2 | Recruiting | Aug 2026 | ≤ 11 d | 2026-07-16 |
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| TEM | Tempus AI | Tempus Priority Study: A Pan-tumor Observational StudyNCT05179824observationalCreate robust data set of health information | — | Active, not recruiting | 2026-10-19 | in 60 d | 2025-05-06 |
November 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ABBV | AbbVie | Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian CancerNCT05456685Overall Response Rate (ORR) | Phase 2 | Active, not recruiting | Nov 2026 | ≤ 102 d | 2025-10-28 |
December 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| GNLX | Genelux Corporation | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)NCT05281471Progression-free survival (PFS) by RECIST 1.1 in the Intention-to-Treat (ITT) population (all randomized participants regardless of whether they received any dose of treatment) | Phase 3 | Recruiting | Dec 2026 | ≤ 133 d | 2026-07-10 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Primary Peritoneal Cancer
most recently updated first68 studies match.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NXTC | NextCure, Inc. | $30M | A Phase I Study of SIM0505 in Participants With Advanced Solid TumorsNCT06792552dose escalation: Dose-limiting toxicity (DLT) | Phase 1 | Recruiting | Drug: SIM0505 for injection, SIM0505 for injection | Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC), Papillary Renal Cell Carcinoma (Prcc), Uterine Serous Carcinoma (USC), NSCLC (Non-small Cell Lung Cancer), Primary Peritoneal Cancer | 738 | 2025-02-26 | Feb 2028 | ≤ 558 d | 2026-08-17 |
| ABBV | AbbVie | $457.5B | A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.NCT06890338Objective Response (OR) by Independent Central Review (ICR) | Phase 2 | Recruiting | Drug: Carboplatin, Mirvetuximab Soravtansine, Bevacizumab | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant | 140 | 2025-11-21 | Feb 2030 | ≤ 1,288 d | 2026-08-14 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian CancerNCT06787612Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by investigator assessment | Phase 2 | Recruiting | Drug: Ubamatamab, Bevacizumab, Cemiplimab, Fianlimab, PLD, Sarilumab, REGN10597 | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 297 | 2025-05-28 | 2028-06-30 | in 680 d | 2026-08-12 |
| LLY | Eli Lilly and Company | $1.15T | A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerNCT07213804Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator | Phase 3 | Recruiting | Drug: Sofetabart Mipitecan, Paclitaxel, Topotecan, Gemcitabine, Pegylated liposomal doxorubicin (PLD), MIRV, Bevacizumab, Carboplatin | Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis | 1,630 | 2025-10-22 | Nov 2028 | ≤ 833 d | 2026-08-06 |
| IMNN | Imunon | $9M | Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal CancerNCT05739981Minimal Residual Disease | Phase 1/2 | Recruiting | Drug: Paclitaxel, Carboplatin, Bevacizumab, IMNN-001 | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 30 | 2023-02-10 | 2027-06-30 | in 314 d | 2026-08-04 |
| IMNN | Imunon | $9M | Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal CancerNCT06915025Overall Survival | Phase 3 | Recruiting | Drug: IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer), Paclitaxel, Carboplatin, Olaparib, Niraparib | Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 500 | 2025-07-09 | 2032-10-31 | in 2,264 d | 2026-08-04 |
| CORT | Corcept Therapeutics | $12.8B | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological CancersNCT06906341Progression-Free Survival (PFS) | Phase 2 | Recruiting | Drug: Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kg | Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer | 270 | 2025-04-11 | Aug 2026 | ≤ 11 d | 2026-07-16 |
| GNLX | Genelux Corporation | $118M | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)NCT05281471Progression-free survival (PFS) by RECIST 1.1 in the Intention-to-Treat (ITT) population (all randomized participants regardless of whether they received any dose of treatment) | Phase 3 | Recruiting | Biological: olvimulogene nanivacirepvec · Drug: Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, Bevacizumab (or biosimilar) | Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma | 186 | 2022-08-31 | Dec 2026 | ≤ 133 d | 2026-07-10 |
| 3402.T | Toray Industries, Inc | $12.6B | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid TumorsNCT03872947Frequency of patients experiencing treatment emergent adverse events as assessed by CTCAE v5.0 | Phase 1 | Active, not recruiting | Biological: TRK-950, TRK-950, TRK-950 · Drug: Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD | Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer | 138 | 2019-04-26 | Jun 2026 | — | 2026-06-23 |
| ABBV | AbbVie | $457.5B | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal CancerNCT05445778Assess Progression-free survival (PFS) | Phase 3 | Active, not recruiting | Drug: Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab | Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 520 | 2023-03-15 | Apr 2027 | ≤ 253 d | 2026-06-02 |
| MGNX | MacroGenics | $261M | A Study of Lorigerlimab in Participants With Advanced Solid TumorsNCT06730347Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as determined by the investigator | Phase 2 | Recruiting | Biological: Lorigerlimab | Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary, Clear Cell Adenocarcinoma of Vulva, Clear Cell Adenocarcinoma of Vagina, Clear Cell Adenocarcinoma of Cervix, Clear Cell Adenocarcinoma of Uterus, Clear Cell Adenocarcinoma of Fallopian Tube, Clear Cell Adenocarcinoma of Peritoneum, Endometrial Cancer | 80 | 2025-05-01 | Jul 2027 | ≤ 345 d | 2026-06-02 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab SoravtansineNCT06682988Randomized Phase 2 Cohort: Percentage of Participants with Grade >= 2 Treatment-Emergent Corneal Adverse Events (AEs) | Phase 2 | Recruiting | Drug: Mirvetuximab Soravtansine | Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers | 110 | 2025-05-28 | Jul 2026 | — | 2026-05-26 |
| IMNN | Imunon | $9M | Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)NCT03393884PFS | Phase 1/2 | Active, not recruiting | Biological: IMNN-001 · Drug: Carboplatin, Paclitaxel | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 130 | 2018-09-05 | 2024-07-25actual | — | 2026-05-04 |
| ZNTL | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | $264M | A Study of Azenosertib (ZN-c3) in Patients With Ovarian CancerNCT04516447Part 1: To investigate the safety and tolerability of azenosertib in combination with PLD, carboplatin, paclitaxel, or gemcitabine | Phase 1 | Recruiting | Drug: Azenosertib, Carboplatin, Pegylated liposomal doxorubicin, Paclitaxel, Gemcitabine · Biological: Bevacizumab | Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer | 172 | 2020-10-26 | 2028-06-30 | in 680 d | 2026-04-07 |
| ZNTL | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | $264M | A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian CancerNCT05198804To investigate the safety and tolerability of ZN-c3 in combination with niraparib, including identification of the MTD and RP2D | Phase 1/2 | Completed | Drug: Azenosertib, Niraparib | Ovarian Cancer, Platinum-resistant Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer | 117 | 2022-01-27 | 2025-10-15actual | — | 2026-03-18 |
| ABBV | AbbVie | $457.5B | First in Human Study of IMGN151 in Recurrent Gynaecological CancersNCT05527184Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Active, not recruiting | Drug: IMGN151 | Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cervical Cancer | 256 | 2023-01-11 | Feb 2027 | ≤ 192 d | 2026-02-20 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian CancersNCT06469281Incidence of treatment emergent adverse events (TEAEs) | Phase 1 | Recruiting | Other: 27T51 · Drug: Cemiplimab, Bevacizumab | Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer | 90 | 2024-08-06 | 2030-05-27 | in 1,376 d | 2026-02-03 |
| ABBV | AbbVie | $457.5B | Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube CancersNCT05041257results2026-01-09Objective Response Rate (ORR) Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1]) | Phase 2 | Completed | Drug: Mirvetuximab soravtansine | Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 79 | 2021-10-19 | 2024-12-12actual | — | 2026-01-09 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid TumorsNCT05194072Number of participants with adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns | Drug: Felmetatug Vedotin, Pembrolizumab | Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Adenoid Cystic Carcinoma | 250 | 2022-01-12 | 2025-05-14actual | — | 2026-01-09 |
| STTK | Shattuck Labs, Inc. | $748M | Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian CancersNCT05483933results2025-12-23Evaluate Safety and Tolerability of SL-172154 When Administered With PLD or Mirvetixumab | Phase 1 | Completed | Drug: Pegylated Liposomal Doxorubicin + SL-172154, Mirvetuximab + SL-172154 | Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinoma | 86 | 2022-08-18 | 2025-02-07actual | — | 2025-12-23 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or UbamatamabNCT04590326Incidence of Dose Limiting Toxicities (DLT) | Phase 1/2 | Recruiting | Drug: REGN5668, Cemiplimab, Ubamatamab, Sarilumab, Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer | 612 | 2020-12-08 | 2027-03-25 | in 217 d | 2025-11-21 |
| TNG.PA | Transgene | $231M | A Trial Evaluating TG4050 in Ovarian Carcinoma.NCT03839524results2025-11-14Safety and Tolerability (Adverse Event Reported Per CTCAE v5) | Phase 1 | Completed | Drug: TG4050 | Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Carcinoma | 64 | 2019-12-09 | 2024-10-08actual | — | 2025-11-14 |
| ABBV | AbbVie | $457.5B | Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian CancerNCT05456685Overall Response Rate (ORR) | Phase 2 | Active, not recruiting | Drug: Mirvetuximab soravtansine, Carboplatin | High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer | 125 | 2022-09-28 | Nov 2026 | ≤ 102 d | 2025-10-28 |
| CORT | Corcept Therapeutics | $12.8B | Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerNCT03776812results2025-04-30Progression-free Survival (PFS) | Phase 2 | Completed | Drug: Relacorilant, Nab-paclitaxel | Recurrent Ovarian Cancer, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma | 178 | 2019-04-05 | 2021-03-16actual | — | 2025-10-07 |
| STRO | Sutro Biopharma, Inc. | $365M | REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1NCT05870748Progression Free Survival (PFS) | Phase 2/3 | Terminatedsponsor's stated reason: Due to strategic business considerations, Sutro has deprioritized the development of luveltamab tazevibulin, leading to termination of the REFRaME program. This decision is not related to any safety or efficacy concerns associated with luvelta | Drug: Luveltamab tazevibulin, Pegfilgrastim, Gemcitabine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan | Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer | 600 | 2023-07-12 | 2025-08-26actual | — | 2025-09-23 |
| STRO | Sutro Biopharma, Inc. | $365M | A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian CancerNCT05200364Part 1 - Safety and tolerability of STRO-002/bevacizumab as a combination therapy | Phase 1 | Terminatedsponsor's stated reason: Terminated Early | Drug: STRO-002, Bevacizumab | Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 58 | 2022-03-22 | 2025-06-01actual | — | 2025-09-22 |
| ABBV | AbbVie | $457.5B | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) ExpressionNCT04209855results2024-08-01Progression-free Survival (PFS) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | Phase 3 | Completed | Drug: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin | Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 453 | 2019-12-31 | 2023-03-06actual | — | 2025-08-27 |
| STRO | Sutro Biopharma, Inc. | $365M | Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial CancersNCT03748186Part 1: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability of STRO-002) | Phase 1 | Completed | Drug: STRO-002 | Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 136 | 2019-02-01 | 2024-06-04actual | — | 2025-08-20 |
| MDNAF | Medicenna Therapeutics, Inc. | $22M | A Beta-only IL-2 ImmunoTherapY StudyNCT05086692MDNA11 Recommended Dose for Expansion for monotherapy (mRDE) and Recommended Dose for Expansion for combination (cRDE) | Phase 1/2 | Recruiting | Drug: MDNA11, Pembrolizumab (KEYTRUDA®) | Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer | 115 | 2021-08-27 | 2026-06-30 | — | 2025-07-09 |
| LYEL | Lyell Immunopharma, Inc. | $332M | A Study to Investigate LYL797 in Adults With Solid TumorsNCT05274451Evaluate incidence of dose-limiting toxicities (DLTs) | Phase 1 | Terminatedsponsor's stated reason: Pipeline Reprioritization | Biological: LYL797 | Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC, Platinum-resistant Ovarian Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Endometrioid Tumor, High Grade Serous Carcinoma, Ovarian Epithelial Cancer | 57 | 2022-03-29 | 2024-11-27actual | — | 2025-07-01 |
| LYEL | Lyell Immunopharma, Inc. | $332M | A Biomarker Screening Protocol for Participants With Solid TumorsNCT05891197observationalTo identify participants whose tumors express biomarkers, such as ROR1, that may inform eligibility for active and future Lyell clinical trials | — | Terminatedsponsor's stated reason: Pipeline Reprioritization | — | Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC, Platinum-resistant Ovarian Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Endometrioid Tumor, High Grade Serous Carcinoma, Ovarian Epithelial Cancer | 10 | 2023-05-19 | 2025-02-05actual | — | 2025-07-01 |
| CLDX | Celldex Therapeutics | $3.3B | A Study of CDX-585 in Patients With Advanced MalignanciesNCT05788484Dose escalation: To determine the maximum tolerated dose of CDX-585 and to select the CDX-585 dose(s) for evaluation in tumor-specific expansion cohorts | Phase 1 | Completed | Drug: CDX-585 | Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Bladder Urothelial Carcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Renal Cell Carcinoma, Cholangiocarcinoma, Pancreatic Cancer, Other Solid Tumors | 20 | 2023-05-11 | 2025-05-21actual | — | 2025-06-15 |
| TEM | Tempus AI | $8.6B | Tempus Priority Study: A Pan-tumor Observational StudyNCT05179824observationalCreate robust data set of health information | — | Active, not recruiting | Other: Observation | Breast Cancer, Prostate Cancer, Bladder Cancer, Lung Cancer, Brain Cancer, Pancreatic Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Cancer of Liver, Cancer of Colon, Cancer of Head and Neck, Cancer of Stomach, Cancer of Gastrointestinal Tract, Cancer of Rectum, Cancer of Esophagus, Cancer of Skin, Cancer of Cervix, Cancer of Kidney, Cancer of Larynx, Cancer of Endometrium, Cancer of the Bile Duct, Cancer of Vulva, Cancer of Bone and Connective Tissue, Leukemia, Lymphoma, Spinal Cord Cancer | 1,000 | 2020-10-19 | 2026-10-19 | in 60 d | 2025-05-06 |
| CORT | Corcept Therapeutics | $12.8B | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube CancerNCT05257408Progression-free Survival as Assessed by BICR | Phase 3 | Active, not recruiting | Drug: Nab-paclitaxel 80 mg/m^2, Relacorilant 150 mg once daily (QD), Nab-paclitaxel 100 mg/m^2 | Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms | 381 | 2022-06-29 | 2025-03-24actual | — | 2025-04-16 |
| PFE | Pfizer | $155.3B | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various CancerNCT04889495observationalSafety profile | — | Withdrawnsponsor's stated reason: The study was withdrawn due to global supply chain issue. Zirabev was not launching in Korea. | Drug: Zirabev | Non-small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Metastatic Kidney Cancer, Cervical Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 0 | 2025-05-16 | 2025-08-16 | — | 2025-03-19 |
| BPTH | Bio-Path Holdings, Inc. | $2M | BP1001-A in Patients With Advanced or Recurrent Solid TumorsNCT04196257Identify Dose Limiting Toxicity (DLT) of BP1001-A | Phase 1 | Recruiting | Drug: BP1001-A (Liposomal Grb2 Antisense Oligonucleotide), BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel | Solid Tumor, Adult, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Endometrial Cancer, Peritoneal Cancer, Solid Tumor | 50 | 2022-08-19 | Jul 2027 | ≤ 345 d | 2025-03-07 |
| STTK | Shattuck Labs, Inc. | $748M | Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian CancerNCT04406623results2025-01-30Safety Profile of SL-172154 | Phase 1 | Completed | Drug: SL-172154 | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 27 | 2020-06-29 | 2023-02-02actual | — | 2025-01-30 |
| PFE | Pfizer | $155.3B | Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian CancerNCT05261490results2024-10-31Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs) | Phase 1/2 | Terminatedsponsor's stated reason: A business decision was made by Pfizer to terminate and remove the Phase 2 expansion of this study for administrative reasons. The reason for study termination is not due to any safety concerns or requests from regulatory authorities. | Drug: maplirpacept (PF-07901801), Pegylated Liposomal Doxorubicin (PLD) | Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | 10 | 2022-08-01 | 2023-10-11actual | — | 2024-11-19 |
| PGEN | Precigen, Inc | $2.4B | Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal CancerNCT03907527Incidence of adverse events | Phase 1 | Active, not recruiting | Biological: PRGN-3005 UltraCAR-T cells, PRGN-3005 UltraCAR-T cells | Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC V8, Stage III Ovarian Cancer AJCC V8, Stage III Primary Peritoneal Cancer AJCC V8, Stage IIIA Fallopian Tube Cancer AJCC V8, Stage IIIA Ovarian Cancer AJCC V8, Stage IIIA Primary Peritoneal Cancer AJCC V8, Stage IIIA1 Fallopian Tube Cancer AJCC V8, Stage IIIA1 Ovarian Cancer AJCC V8, Stage IIIA2 Fallopian Tube Cancer AJCC V8, Stage IIIA2 Ovarian Cancer AJCC V8, Stage IIIB Fallopian Tube Cancer AJCC V8, Stage IIIB Ovarian Cancer AJCC V8, Stage IIIB Primary Peritoneal Cancer AJCC V8, Stage IIIC Fallopian Tube Cancer AJCC V8, Stage IIIC Ovarian Cancer AJCC V8, Stage IIIC Primary Peritoneal Cancer AJCC V8, Stage IV Fallopian Tube Cancer AJCC V8, Stage IV Ovarian Cancer AJCC V8, Stage IV Primary Peritoneal Cancer AJCC V8, Stage IVA Fallopian Tube Cancer AJCC V8, Stage IVA Ovarian Cancer AJCC V8, Stage IVA Primary Peritoneal Cancer AJCC V8, Stage IVB Fallopian Tube Cancer AJCC V8, Stage IVB Ovarian Cancer AJCC V8, Stage IVB Primary Peritoneal Cancer AJCC V8 | 71 | 2019-04-30 | 2024-12-15 | — | 2024-11-08 |
| IMNN | Imunon | $9M | Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian CancerNCT02480374DLT | Phase 1 | Completed | Biological: IMNN-001 | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 18 | Sep 2015 | May 2017actual | — | 2024-10-02 |
| KZIA | Kazia Therapeutics Limited | — | Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.NCT02903771results2024-09-19Determination of the Maximum Tolerated Dose (MTD) | Phase 1 | Completed | Drug: Part A: Dose Escalation of Cantrixil, Part B: Expansion Cohort of Cantrixil | Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms | 32 | 2016-12-05 | 2020-03-24actual | — | 2024-09-19 |
| CLDX | Celldex Therapeutics | $3.3B | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesNCT03329950Safety and Tolerability of CDX-1140 as assessed by CTCAE v5.0 | Phase 1 | Completed | Drug: CDX-1140, CDX-301, pembrolizumab, Chemotherapy | Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, Pancreatic Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Other Solid Tumors, Diffuse Large B-cell Lymphoma (DLBCL), Mantle Cell Lymphoma, Indolent B-cell Lymphomas, Non-Hodgkin Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Waldenstrom's Disease, Marginal Zone Lymphoma, Mucosa Associated Lymphoid Tissue, Small Lymphocytic Leukemia | 132 | 2017-12-01 | 2022-09-13actual | — | 2024-03-28 |
| SNDX | Syndax Pharmaceuticals | $1.8B | Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian CancerNCT02915523results2024-01-10Phase 2: Progression Free Survival (PFS), as Determined by the Local Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) | Phase 1/2 | Completed | Drug: entinostat, avelumab, Placebo | Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 140 | 2016-12-19 | 2019-02-21actual | — | 2024-01-10 |
| CLDX | Celldex Therapeutics | $3.3B | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced MalignanciesNCT04440943Safety and Tolerability of CDX-527 as assessed by CTCAE v5.0 | Phase 1 | Completed | Drug: CDX-527 | Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, MSI-H Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Other Solid Tumors | 27 | 2020-08-04 | 2023-04-06actual | — | 2023-06-18 |
| XNCR | Xencor, Inc. | $1.9B | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsNCT03849469Safety and tolerability profile of XmAb22841 assessed by rates of treatment-related adverse events (AEs), graded by CTCAE v4.03. | Phase 1 | Completed | Biological: XmAb®22841, Pembrolizumab (Keytruda®) | Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma | 78 | 2019-05-29 | 2023-02-16actual | — | 2023-03-30 |
| MXCT | MaxCyte, Inc. | $131M | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal MesotheliomaNCT03608618Incidence and severity of adverse events as assessed by CTCAE v.5.0 | Phase 1 | Terminatedsponsor's stated reason: Sponsor shift in focus | Biological: MCY-M11 · Drug: Cyclophosphamide | Peritoneal Mesothelioma, Fallopian Tube Adenocarcinoma, Adenocarcinoma of the Ovary, Primary Peritoneal Carcinoma | 14 | 2018-08-27 | 2021-02-11actual | — | 2021-09-05 |
| BSX | Boston Scientific Corporation | $73.1B | Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of MalignancyNCT03593681results2021-01-20observationalSensitivity and Specificity of Cytological Samples for Fallopian Tube Involvement | — | Completed | Device: Hysteroscopic cell sampling of the fallopian tube | Fallopian Tube Cancer, Ovarian Cancer, Ovarian Neoplasms, Ovary Cancer, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, High Grade Serous Carcinoma, Peritoneal Carcinoma, Peritoneal Neoplasms, Adnexal Mass, Ovarian Diseases | 150 | 2018-08-27 | 2020-02-14actual | — | 2021-01-20 |
| IPN.PA | Ipsen | $15.5B | Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal CarcinomatosisNCT00216372Percentage of responder patients (patient with 1 or less vomiting episode per day during at least 3 consecutive days or in whom nasogastric tube (NGT) has been removed during at least three consecutive days without vomiting recurrence) | Phase 3 | Completed | Drug: Lanreotide (microparticle formulation) · Other: Placebo | Intestinal Obstruction, Carcinoma, Peritoneal Neoplasms | 80 | Sep 2003 | Oct 2008actual | — | 2020-11-05 |
| PFE | Array Biopharma, now a wholly owned subsidiary of Pfizer | $155.3B | A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal CancerNCT01649336Establish the recommended Phase 2 dose of study drug administered on continuous and intermittent schedules in combination with paclitaxel. | Phase 1 | Completed | Drug: MEK162, MEK inhibitor; oral, Paclitaxel, mitotic inhibitor; intravenous | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer | 36 | Jul 2012 | Mar 2016actual | — | 2020-09-14 |
| AZN | AstraZeneca | — | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid TumorsNCT02658214Laboratory findings (including: clinical chemistry, hematology, and urinalysis) | Phase 1 | Completed | Drug: paclitaxel + carboplatin, carboplatin + etoposide, gemcitabine + carboplatin, nab-paclitaxel (paclitaxel-albumin) + carboplatin, oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid), nab-paclitaxel (paclitaxel-albumin) + gemcitabine, cisplatin + 5-fluorouracil (5FU) · Biological: durvalumab, tremelimumab | Small Cell Lung Carcinoma, Carcinoma, Squamous Cell of Head and Neck, Stomach Neoplasms, Triple Negative Breast Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Esophagogastric Junction Neoplasms, Carcinoma, Pancreatic Ductal, Esophageal Squamous Cell Carcinoma | 32 | 2016-04-28 | 2019-11-14actual | — | 2020-08-20 |
| AMGN | Amgen | $229.9B | Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal CancerNCT00479817Progression Free Survival | Phase 2 | Completed | Drug: AMG 386, AMG 386, Paclitaxel, AMG 386 Placebo | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 161 | 2007-07-05 | 2009-08-11actual | — | 2019-12-18 |
| LLY | Eli Lilly and Company | $1.15T | Study of Ramucirumab in Ovarian CancerNCT00721162results2014-06-18Percentage of Participants With Progression-Free Survival at 6 Months (PFS-6) | Phase 2 | Completed | Biological: Ramucirumab | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 60 | Aug 2008 | May 2012actual | — | 2019-09-26 |
| LLY | Eli Lilly and Company | $1.15T | A Study LY2228820 for Recurrent Ovarian CancerNCT01663857results2019-05-29Phase 1b: Recommended Phase 2 Dose of LY2228820 in Combination With Gemcitabine and Carboplatin (Maximum Tolerated Dose [MTD]) | Phase 1/2 | Completed | Drug: LY2228820, Carboplatin, Placebo, Gemcitabine | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 118 | Jul 2012 | 2017-05-25actual | — | 2019-09-11 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Chemotherapy Treatment for Patients With Ovarian CancerNCT00428610results2018-04-19Percentage of Participants With Complete Response and Partial Response (Objective Response Rate) | Phase 2 | Completed | Drug: LY573636-sodium | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 103 | Feb 2007 | Feb 2011actual | — | 2018-04-19 |
| AMGN | Amgen | $229.9B | AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)NCT01281254To determine if AMG 386 plus PLD is superior to placebo plus PLD as measured by progression-free survival, defined as the time from randomization to the earliest of the dates of first radiologic disease progression per RECIST 1.1 with modifications | Phase 3 | Terminatedsponsor's stated reason: Closure of long term follow up (LTFU) and study earlier than previously outlined in the protocol as no beneficial information gained from continuing LTFU. | Drug: AMG386 plus PLD, Placebo plus PLD | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer | 223 | 2011-04-18 | 2014-08-29actual | — | 2017-12-02 |
| ABBV | AbbVie | $457.5B | A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer PatientsNCT00526617Maximum Tolerated Dose | Phase 1 | Completed | Drug: ABT-888, Temozolomide | Non-hematologic Malignancies, Metastatic Melanoma, Breast Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Hepatocellular Carcinoma | 41 | Aug 2007 | Jun 2010actual | — | 2017-11-21 |
| AMGN | Amgen | $229.9B | TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian CancerNCT01493505Progression free survival | Phase 3 | Terminatedsponsor's stated reason: Amgen Administrative Decision - termination of LTFU | Drug: AMG 386, Paclitaxel, AMG 386 Placebo, Carboplatin | Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer | 1,015 | Jan 2012 | Mar 2016actual | — | 2017-02-23 |
| AMGN | Amgen | $229.9B | TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube CancerNCT01204749Progression-Free Survival | Phase 3 | Completed | Drug: AMG 386, AMG 386 Placebo, Paclitaxel, Paclitaxel | Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer | 919 | Nov 2010 | Mar 2013actual | — | 2016-12-15 |
| AMGN | Amgen | $229.9B | Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian CancerNCT01253681To evaluate whether AMG 386 in combination with paclitaxel and carboplatin is safe and well tolerated in the first-line treatment of high-risk stage I and stages II-IV epithelial ovarian, primary peritoneal and fallopian tube cancers. | Phase 1 | Completed | Drug: AMG 386, paclitaxel and carboplatin | Carcinoma, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer | 27 | Nov 2010 | Oct 2012actual | — | 2015-10-14 |
| SNY | Sanofi | — | Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerNCT00677079Best overall response | Phase 2 | Completed | Drug: Iniparib | Primary Peritoneal Cancer, Advanced Epithelial Ovarian Cancer | 12 | Jun 2008 | Dec 2008actual | — | 2013-10-01 |
| LLY | Eli Lilly and Company | $1.15T | Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal CancerNCT00489359results2011-06-16Phase 1 - Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Carboplatin | Phase 1/2 | Completed | Drug: Pemetrexed - Phase 1, Carboplatin - Phase 1, Pemetrexed - Phase 2, Carboplatin - Phase 2 | Ovarian Cancer, Primary Peritoneal Cancer | 86 | Jul 2005 | Feb 2010actual | — | 2011-06-16 |
| LLY | Eli Lilly and Company | $1.15T | An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior ChemotherapyNCT00191646results2010-09-09Progression Free Survival (PFS) | Phase 3 | Completed | Drug: Gemcitabine, Paclitaxel, Carboplatin | Genital Neoplasms, Female, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pelvic Neoplasms, Peritoneal Neoplasms | 919 | Oct 2002 | Aug 2009actual | — | 2011-03-04 |
| LLY | Eli Lilly and Company | $1.15T | Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube CancerNCT00063401To determine the progression-free survival obtained with cetuximab (C225)/paclitaxel/carboplatin in subjects with newly diagnosed advanced stage ovarian, primary peritoneal, or fallopian tube cancer. | Phase 2 | Completed | Biological: Cetuximab: · Drug: Paclitaxel, Carboplatin | Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Neoplasms | 39 | Sep 2003 | Jun 2006actual | — | 2010-04-08 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal CancerNCT00461786results2009-08-24Tumor Response | Phase 2 | Completed | Drug: pemetrexed | Ovarian Cancer, Peritoneal Cancer | 51 | Sep 2004 | Oct 2007actual | — | 2009-12-04 |
| LLY | Eli Lilly and Company | $1.15T | Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based ChemotherapyNCT00109096To assess the anti-tumor activity, as measured by tumor response rate (proportion of patients with complete or partial response, of 500 mg/m2 vs. 900 mg/m2 of pemetrexed therapy administered every 21 days | Phase 2 | Completed | Drug: Pemetrexed | Ovarian Neoplasms, Primary Peritoneal Cancer | 100 | Jun 2005 | — | — | 2007-05-17 |
| LLY | Eli Lilly and Company | $1.15T | A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.NCT00191607- Progression free survival (PFS) in patients who have failed one, but no more than two, prior treatments | Phase 3 | Completed | Drug: Gemcitabine, liposomal doxorubicin | Genital Neoplasms, Female, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pelvic Neoplasms, Peritoneal Neoplasms | 162 | Jul 2002 | — | — | 2007-01-26 |
| PFE | Pfizer | $155.3B | Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube CancerNCT00074867At the completion of Stage 1 of the study, it did not meet the objective response criteria to proceed to Stage 2 of the trial. | Phase 2 | Completed | Drug: CP-547,632 | Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms | 29 | Oct 2003 | — | — | 2006-11-07 |
| LLY | Eli Lilly and Company | $1.15T | Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal CancerNCT00055432 | Phase 2 | Terminated | Drug: Gemzar and Alimta | Ovarian Cancer, Peritoneal Cancer | — | — | — | — | 2006-09-15 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Primary Peritoneal Cancer is matched — 7 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Primary Peritoneal Cancer
- Primary Peritoneal Carcinoma
- Peritoneal Neoplasms
- Peritoneal Cancer
- Platinum-Resistant Primary Peritoneal Carcinoma
- Peritoneal Carcinoma
- Recurrent Primary Peritoneal Carcinoma
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Primary Peritoneal Cancer” (a text search, wider than this page)